FDA Approves Elon Musk’s Neuralink Study

Elon Musk’s Neuralink Study Receives FDA Approval for Human Clinical Trial.- Elon Musk’s brain-implant startup, Neuralink, has obtained approval from the U.S. Food and Drug Administration (FDA) to commence its groundbreaking human clinical study.

The company is dedicated to developing a revolutionary device that allows individuals to control computer interfaces using their brain activity. Also, Neuralink’s innovative devices hold the potential to restore vision and empower individuals with severe disabilities to communicate and move by decoding brain signals.

In its pursuit, Neuralink envisions establishing specialized clinics where surgical robots will implant the devices directly into patients’ brains. Employing cutting-edge technology, the robot surgeon meticulously inserts Neuralink’s distinctive electrodes, also known as brain-signal recording wires, into the brain’s neural network.

“We are thrilled to announce that the FDA has granted approval for the launch of our inaugural human clinical study,” declared Neuralink in a tweet. “This momentous achievement is the culmination of the exceptional efforts by the Neuralink team, working closely with the FDA.

Get Bloomberg and WSJ Digital Subscription 5 Years for $129

It signifies a crucial initial step that will pave the way for our technology to benefit countless individuals.”

Acknowledging Neuralink’s announcement, the FDA expressed its support for the company’s breakthrough research.

While Neuralink has not yet initiated recruitment for its trial, the company has confirmed that it will announce further details in the near future.

Back in 2019, Musk had already outlined the company’s intentions to seek FDA approval for human testing, boldly predicting its realization as early as 2020.

Neuralink’s implant technology has undergone extensive testing on primates for several years. In April 2021, the company showcased a remarkable video featuring a monkey implanted with two Neuralink devices, showcasing its ability to play the video game Pong solely through brain control.

During a demonstration in December, Musk revealed a video demonstrating what he referred to as “telepathic typing” performed by a monkey with a Neuralink brain implant. The primate effortlessly maneuvered a cursor using its thoughts to select letter images—a remarkable display of the device’s potential.

Prior to introducing a brain-computer interface to patients, clinical trials must establish the long-term safety and efficacy of Neuralink’s device, as emphasized by experts in the field of neurotechnology.

Get New York Times Subscription and WSJ Digital 5-Years Combo for $129

Addressing concerns raised by the FDA, Musk emphasized the company’s commitment to resolving issues related to device overheating and the potential seepage of toxic substances into the brain. In February 2022, Neuralink reported the unfortunate euthanization of several monkeys due to suspected device-associated infections.

Finally, Neuralink acknowledges that device-associated infections pose inherent risks with any medical device implanted through the skin. Consequently, the company has developed enhanced surgical protocols to mitigate such risks.

The approval granted by the FDA marks a significant milestone for Elon Musk’s Neuralink Study, propelling the field of brain-computer interfaces into a promising future.

The post FDA Approves Elon Musk’s Neuralink Study appeared first on First American News LLC (WSJ Renewal).